Improving theranostics in pancreatic cancer

Area of Science:

• Oncology
• Biotechnology
• Immunotherapy

Background:

• Pancreatic cancer is a highly lethal malignancy, projected to become the second deadliest in the US by 2030.
• Late diagnosis and metastasis significantly reduce patient survival rates, highlighting the need for improved therapeutic strategies.
• Current treatments are insufficient, with a critical need for advancements in detection, surgical intervention, and therapy.

Purpose of the Study:

• To review recent advancements in using monoclonal antibodies (mAbs) for pancreatic cancer treatment.
• To explore chemical and protein engineering strategies for enhancing mAb efficacy.
• To focus on improving mAb homogeneity, stability, and targeted delivery of agents to disease sites.

Main Methods:

• Literature review of recent therapeutic approaches for pancreatic cancer.
• Generation of atomic models for novel therapeutic strategies.
• Analysis of chemical and protein engineering techniques applied to monoclonal antibodies.

Main Results:

• Monoclonal antibodies (mAbs) are being developed to target specific pancreatic cancer markers.
• Engineering efforts focus on enhancing mAb properties like homogeneity and stability.
• Improved mAb administration aims for precise delivery of imaging agents and cytotoxins.

Conclusions:

• Monoclonal antibodies represent a promising avenue for pancreatic cancer therapy.
• Chemical and protein engineering are crucial for optimizing mAb-based treatments.
• Enhanced mAbs can improve targeted delivery, potentially leading to better patient outcomes.